Skip to content


  • Research article
  • Open Access
  • Open Peer Review

The influence of LV geometry on the occurrence of abnormal exercise tests in athletes

BMC Cardiovascular Disorders201919:6

  • Received: 5 June 2018
  • Accepted: 17 December 2018
  • Published:
Open Peer Review reports



Previous studies revealed a high rate of abnormal exercise test (ET) results in the absence of obstructive coronary artery disease (CAD) in asymptomatic athletes. The physiological background of this phenomenon is not well established. In particular, it is unclear whether sports-induced morphological cardiac adaptations are determinants of abnormal ET results. The main objective of this study was to investigate if healthy asymptomatic recreational and competitive athletes with abnormal ET results without obstructive CAD have a higher LV mass when compared with athletes with normal ET results.


Seventy-three athletes with abnormal ET results without presence of obstructive CAD underwent echocardiographic assessment of LV mass, systolic and diastolic measurements. These data were compared with data from 73 athletes with normal ET results, matched for gender, age, body composition, sports characteristics and exercise capacity.


No significant increase in LV mass (161.9 ± 39 g vs. 166.9 ± 42.1 g, p = 0.461) was found between groups. Athletes with abnormal ET results had a significant thicker IVSd (9.7 ± 1.8 mm vs. 9.0 ± 1.7 mm, p = 0.014), higher IVSd/PWTd ratio (1.08 ± 0.20 vs. 1.00 ± 0.12, p = 0.011) and deceleration time (DT) was prolonged ((225.14 ± 55.08 vs. 199.96 ± 34.65, p = 0.003).


Athletes with abnormal ET result did not show a higher in LV mass when compared to athletes with a normal ET result. However, a pattern of asymmetric cardiac remodeling, together with altered diastolic function is present. Due to small differences, cardiac remodeling only plays a limited role in the occurrence of positive ET results in athletes.


  • Athletes
  • Exercise testing
  • Diagnostic accuracy
  • Cardiac remodeling
  • Echocardiography


In order to obtain sports eligibility, athletes often undergo pre-participation screening (PPS) to identify genetic, congenital and/or acquired heart diseases in order to prevent the occurrence of sudden cardiac death (SCD) [1, 2]. In 1982, The first PPS protocol was introduced in Italy and effectively reduced cardiac events and SCD in young, active individuals [3]. Since then, several protocols have been established but many failed to identify those individuals with potentially lethal cardiac conditions [4]. Therefore, in addition to a general evaluation of the athlete’s overall health, a 12-lead resting electrocardiogram (ECG) was added in PPS protocols [5]. The ECG has proven to be an effective screening method as more than 80% of the individuals with underlying cardiac disorders, which account for the majority of SCD cases, had an abnormal ECG during PPS [6]. Because most exercise-related cardiovascular events occur during exericse, PPS also often includes exercise testing (ET), which is considered a low-cost non-invasive component for detection of myocardial ischemia in recreational and competitive athletes. However, several studies demonstrated a high prevalence of abnormal ET results, indicative for myocardial ischemia, in athletes in the absence of obstructive coronary artery disease (CAD [79]. Whereas this observation may be explained partly by a low a priori risk of CAD as compared to non-athletes, other sport-related explanations have also been proposed. First, exercise-induced ST-segment depression in athletes may be caused by microvascular dysfunction, inadequate density of myocardial capillaries relative to myocardial mass and compression of the microvascular arteries [10]. This theory is supported by a previous study [11] which showed that microvascular function and increase of capillary density is critically dependent on age. In older subjects, the increase in left ventricular mass outweighs the increase in capillary density and the microvascular function is altered in these subject when compared with younger subjects leading to a mismatch in oxygen demand and oxygen supply. Second, cardiac remodeling may play a role. In fact, different types of exercise training (endurance and strength) affect the cardiovascular system in different manners. This leads to various cardiac adaptations, including structural, functional and electrical changes, often referred to as “the athlete’s heart” [12]. Whereas electrical remodeling, including rest repolarization abnormalities, is known to induce false-positive ET results [13], the influence of morphological remodeling on ET results in athletes is not well established. In the general population, LV hypertrophy and hypertrophic cardiomyopathy were shown to be related to ST-segment depression independent from macrovascular CAD [10]. However, it remains unclear whether a sports-induced increase in LV mass, which is the most common morphological cardiac adaptation [12, 14], is a determinant of abnormal ET results.

Therefore, the main objective of this study is to investigate if healthy asymptomatic recreational and competitive athletes with abnormal ET results without obstructive CAD have a higher LV mass when compared with athletes with normal ET results.


Study design and population

This study was conducted as part of a single-center prospective study in asymptomatic recreational and competitive athletes who underwent PPS at Máxima Medical Center, Veldhoven, The Netherlands, between October 2014 and March 2017 and was approved by the local medical ethical committee. The main objective of the primary study was to investigate the oxygen uptake patterns during cardiopulmonary exercise testing in order to evaluate if microvascular dysfunction could play a role in the occurrence of abnormal ET results without obstructive CAD in athletes. In the primary study, athletes were defined as those who have practiced sports for at least 2.5 h a week for at least 30 weeks per year [15]. Athletes were excluded if they had complaints suggestive of cardiac disease (such as chest pain or impaired exercise tolerance). The exercise protocol that was used is extensively documented in the primary study [16]. An abnormal exercise test was defined as a minimum of 0.1 mV horizontal or downsloping ST-segment depression or elevation measured at least 80 or 60 ms after the J-point during exercise or recovery in three consecutive beats [13]. Athletes with abnormal ET results were referred to a cardiologist for further diagnostic evaluation including echocardiography, myocardial perfusion imaging and coronary angiography to rule out obstructive CAD. After written informed consent, subjects with abnormal ET result were included in the analysis. To evaluate if athletes with abnormal ET results without obstructive CAD have a higher LV mass when compared with athletes with normal ET results, athletes with abnormal ET results were matched 1:1 with athletes with normal ET results. Athletes who participated in the primary study and underwent echocardiography at Máxima Medical Center were selected for matching. The athletes with abnormal ET results were matched with athletes with normal ET results according to gender (1:1), age (+/− 3 years), body mass index (BMI) (+/− 0.5 kg/m2), body surface area (BSA) (+/− 0.2 m2), hours of sports per week (+/− 1 h), sport category (1:1) and maximal workload per kilogram (+/− 0.3 W/kg).

Data collection

The following cardiovascular risk factors were collected through a questionnaire: hypertension, hypercholesterolemia, diabetes, use of tobacco and family history. This questionnaire also addressed the type of sports each athlete plays according to the Mitchell Classification of Sports [17] and the intensity of the sport (training hours per week). In addition, the following variables were obtained from the exercise test: resting mean arterial pressure (MAP), MAP at peak exercise, resting heart rate, maximal achieved heart rate, percentage of maximal predicted heart rate, maximal achieved workload and percentage of the predicted maximal workload.

Resting electrocardiography

In all athletes, a 12-lead resting ECG was recorded in the supine position prior to the exercise test. The ECGs were analyzed following the international recommendations for the interpretation of ECGs in athletes [5]. The ECGs were classified as normal ECG findings or abnormal ECG findings that require further evaluation.


The athletes with a positive test result and who were referred to the department of cardiology received an echocardiogram including standard two-dimensional color, spectral Doppler measurements and additional measurements for cardiac remodeling to current standards [18]. Experienced senior echocardiography technicians, who were blinded for the initial abnormal ET result, performed the echocardiographic examination. Two individual cardiologists reported and validated the echocardiographic examination, both were not blinded for the initial abnormal ET result. For the calculation of the LV mass, the left ventricular end diastolic diameter (LVEDD), the end diastolic interventricular septal wall thickness (IVSd) and the end diastolic left ventricle posterior wall thickness (PWTd) were measured in millimeters from the parasternal long axis view. The following formula was used to calculate the LV mass in grams: 0.8 x (1.04 x (LVEDD + IVSd + PWTd)3 – (LVEDD)3) + 0.6. For the calculation of the relative wall thickness (RWT), the following formula was used: (IVSd + PWTd)/LVEDD [19]. To establish the cardiac diastolic function, the following echocardiographic parameters were measured: the maximal early ventricular filling velocity (E); the deceleration time (DT) of the early filling velocity; the maximal late ventricular filling velocity due to the atrial kick (A); the E/A ratio; the diastolic peak velocities of the mitral annulus measured at the interventricular septum and laterally, designated as E’ interventricular septum and E’ lateral, respectively; and the E/E’ ratio for both annulus measurements.

Statistical analysis

Data were analyzed using SPSS 22 statistical software (SPSS Inc., Chicago, Illinois, USA). The distribution of all continuous variables was assessed using the Shapiro-Wilk test, and presented as mean ± SD or median (interquartile range). Between-group differences were assessed using one-way-analysis-of-variance to compare continuous parametric data and the Mann-Whitney U test for non-parametric data. Categorical data are presented as numbers and percentages and the chi-square test was used for between-group differences. A p-value of 0.05 was considered to be statistically significant.


From a cohort of 753 athletes (mean age 45.7 ± 14.7 years, 81% male), 73 athletes (mean age 53.4 ± 9.6 years, 9.7%) with a positive ET result and who underwent echocardiography were selected (Fig. 1). All these athletes were referred to the department of cardiology for further diagnostic evaluation. Myocardial perfusion scintigraphy (MPS) was used in 57 athletes (78%), computed tomography coronary angiography (CCTA) was used in 15 athletes (21%) and direct coronary angiography was used in 1 athlete (1%). Diagnostic evaluation showed no abnormalities, suggestive for myocardial ischemia or significant coronary artery disease in 66 athletes (90%). Seven athletes (10%) showed a mean of 1.9 ± 1.1 ischemic segments of ischemia on MPS and subsequent CAG showed no obstructive CAD in all of these athletes. So, in all 73 athletes, no obstructive CAD was found. These 73 athletes were matched with athletes with normal ET results according to gender, age, BMI, BSA, hours of sports per week, sports category and maximal workload per kilogram as described above. Table 1 summarizes the characteristics of athletes with abnormal ET result who underwent echocardiography and of the matched control group with a negative exercise test. The study population consisted primarily of male athletes (86.3%), most frequently practicing high-static and high-dynamic sports (68.5%) of which cycling was the predominant practiced sport (n = 41, 82%). Soccer was the predominant practiced sport in the low-static/high-dynamic classified sports (n = 15, 71%).
Fig. 1
Fig. 1

Flowchart of the study, Legend: ET, exercise testing

Table 1

Comparison of the matched characteristics between athletes with abnormal ET results and the matched control group with normal ET results


Abnormal ET results (n = 73)

Normal ET results (n = 73)


Male gender, n (%)

63 (86.3)

63 (86.3)


Age (years)

53.4 ± 9.6

52.4 ± 9.5


BSA (m2)

1.97 ± 0.18

1.98 ± 0.16


BMI (kg.m− 2)

23.85 ± 2.6

24.63 ± 2.34


Hours sport/week

6.4 ± 3.5

6.7 ± 3.3


Sports classification, n (%)

 ▪ HS/HD

50 (68.5)

50 (68.5)


 ▪ LS/HD

21 (28.8)

21 (28.8)


 ▪ MS/MD

2 (2.7)

2 (2.7)


Workload per kilogram (−1)

4.32 ± 0.94

4.22 ± 0.92


ECG findings




63 (86.3)

68 (93.2)



10 (13.7)

5 (6.8)


Diagnostic evaluation, n (%)


57 (78.1)



15 (20.5)



1 (1.4)


Outcome diagnostic evaluation, n (%)


66 (90.4)




7 (9.6)


Ischemic segments, mean

1.9 ± 1.1


Obstructive CAD, n



ET exercise testing, BSA body surface area, BMI body mass index, HS high static, HD high dynamic, LS low static, HD high dynamic, MS mid static, MD mid dynamic, W workload, MPS myocardial perfusion scintigraphy, CT computed tomography coronary angiography, CAG coronary angiography, CAD coronary artery disease

The comparison of the exercise parameters between athletes with abnormal ET results and the athletes with normal ET results are demonstrated in Table 2. No significant differences were observed in MAP at peak exercise, heart frequency at rest, maximal achieved workload and percentage of the predicted maximal workload. The maximal heart rate (174.8 ± 16.5 bpm vs. 167.8 ± 14.5 bpm, p = 0.007) and the percentage of the predicted maximal heart rate (99.7 ± 8.0 versus 95.4 ± 7.7, p = 0.001) were significantly higher in the group with the abnormal ET results. The MAP at rest was also lower in the group with the abnormal ET results (97.2 ± 10.4 vs. 102.1 ± 11.9 mmHg).
Table 2

Comparison of exercise parameters between athletes with abnormal and normal ET results


Abnormal ET results (n = 73)

Normal ET results (n = 73)


Rest MAP (mmHg)

97.2 ± 10.4

102.1 ± 11.9


Max MAP (mmHg)

119.5 ± 12.3

121.6 ± 11.9


Rest HF (bpm)

66.3 ± 13.9

67.8 ± 13.6


Max HF (bpm)

174.8 ± 16.5

167.8 ± 14.5


% pred HF max

99.7 ± 8.0

95.4 ± 7.7


Wmax (watt)

331.8 ± 73.2

331.9 ± 72.2


% pred Wmax

152.6 ± 22.6

153.8 ± 26.2


*P < 0.05

ET exercise testing, Rest variables measured in rest, Max variables measured at maximal exercise, MAP mean arterial pressure, HF heart frequency, % pred HF max percentage predicted maximal heart frequency, Wmax maximal workload, % pred Wmax, percentage predicted maximal workload

Table 3 shows the echocardiographic findings in athletes with abnormal ET results and the athletes with normal ET results. Athletes with abnormal ET results showed no significant increased LV mass when compared with athletes with normal ET results (161.9 ± 39 g vs. 166.9 ± 42.1 g, p = 0.461). When corrected for the BSA, also no significant difference was observed between the two groups (82.1 ± 18 g.m-2 vs. 84.2 ± 19.9 g.m-2, p = 0.501). The LVEDD was significantly lower in athletes with abnormal ET result (48.4 ± 4.4 mm vs. 51.0 ± 5.3 mm, p = 0.002). The end diastolic IVS was significantly thicker in the group of athletes with abnormal ET result (9.7 ± 1.8 mm vs. 9.0 ± 1.7 mm, p = 0.014). No significant difference was observed in the end diastolic PWT between the two groups (p = 0.718). There was a significantly higher IVSd/PWTd ratio (1.08 ± 0.20 vs. 1.00 ± 0.12, p = 0.011) and RWT (0.38 ± 0.06 vs. 0.36 ± 0.06, p = 0.044) in athletes with abnormal ET result. Regarding indicators of LV diastolic function, there was no significant difference in early ventricular filling velocity (E), late ventricular filling velocity (A) and the E/A ratio between the two groups (p = 0.281, p = 0.762, p = 0.363, respectively). Yet, the deceleration time of the early filling velocity was significantly prolonged in athletes with abnormal ET results (225.14 ± 55.08 vs. 199.96 ± 34.65, p = 0.003). No significant difference was found in the E/E’ septal and lateral ratio between the two groups (p = 0.904, p = 0.936, respectively).
Table 3

Echocardiographic findings in athletes with abnormal and normal ET results


Abnormal ET results (n = 73)

Normal ET results (n = 73)


LV mass (g)

161.9 ± 39.0

166.9 ± 42.1


LV mass/BSA (g.m− 2)

82.1 ± 18.0

84.2 ± 19.9


LVEDD (mm)

48.4 ± 4.4

51.0 ± 5.3


IVSd (mm)

9.7 ± 1.8

9.0 ± 1.7


PWTd (mm)

9.1 ± 1.4

9.0 ± 1.4


LVESD (mm)

32.3 ± 2.7

34.1 ± 4.4


ESWS (− 2)

66.7 ± 16.3

81.8 ± 26.3

< 0.001*

IVSd/PWTd ratio

1.08 ± 0.20

1.00 ± 0.12



0.38 ± 0.06

0.36 ± 0.06


MV max flow E (m.s− 1)

0.694 ± 0.160

0.724 ± 0.160


MV DT E (ms)

225.14 ± 55.08

199.96 ± 34.65


MV max flow A (m.s− 1)

0.591 ± 0.143

0.584 ± 0.111


E/A ratio

1.22 ± 0.33

1.28 ± 0.36


E/E’ septal ratio

7.73 ± 1.91

7.69 ± 1.62


E/E’ lateral ratio

5.68 ± 1.58

5.77 ± 1.64


*P < 0.05

ET exercise testing, LV left ventricular, LVEDD left ventricular end diastolic diameter, IVSd interventricular septal wall thickness at diastole, PWTd posterior wall thickness at diastole, RWT relative wall thickness, MV max flow E, maximal early ventricular filling velocity, MV DT E deceleration time of the early filling velocity, MV max flow A maximal late ventricular filling velocity, E’ septal diastolic peak velocity of the mitral annulus measured at the interventricular septum, E’ lateral diastolic peak velocity of the mitral annulus measured lateral


This study showed that athletes with a positive ET result in the absence of obstructive CAD do not have a higher LV mass than athletes with normal ET results. These athletes, however, did show a smaller LVEDD, a higher RWT and asymmetric remodeling due to an increased IVS thickness, as well as a prolongation of the DT of the early filling velocity of the LV suggestive of an altered diastolic function. It should be acknowledged that these differences were small and values were still within the normal range. Therefore, these results suggest that sport-induced morphological adaptations only play a limited role in the development of STT changes during exercise.

To the authors’ knowledge, this is the first prospective study evaluating the relationship between LV remodeling and ET results in healthy asymptomatic athletes. In the present study, there was no significant difference in absolute LV mass and LV mass indexed to BSA between the athletes with abnormal ET results and the athletes with normal ET results. These findings are in line with previous studies [20, 21] that include smaller study populations. Despite the fact that the present study did not show a relationship between LV mass and abnormal ET results, the RWT was significantly higher in athletes with abnormal ET results than in athletes with a normal ET result (0.38 ± 0.06 versus 0.36 ± 0.06, p = 0.044). The present study also showed a significantly decreased LVEDD and increased IVS thickness at the end diastole in athletes with abnormal ET results, leading to a significantly higher IVS/PWT ratio. These findings suggest that athletes with abnormal ET result show a pattern of asymmetric cardiac remodeling.

The two groups of athletes in the present study showed no significant difference in the delivered maximal workload. However, a significantly higher maximum heart rate was observed in athletes with abnormal ET results. According to the Fick principle (V̇O2, max = cardiac output x [arterial - venous O2 difference]), one can assume that there is a reduced stroke volume (SV) in athletes with abnormal ET result, as there is a linear relationship between the workload and V̇O2 [22]. A possible explanation of the reduced SV could be the presence of a smaller left ventricular cavity expressed as a reduction in the LVEDD due to the asymmetric remodeling seen in the present study. The findings of a significant higher achieved maximum heart rate reflect necessary physiological adaptations to the observed cardiac remodeling in order to obtain the necessary increase in cardiac output.

The asymmetric remodeling pattern may be explained by Poiseuille’s law (pressure = flow x resistance). During exercise, and especially in dynamic sports activities, cardiac output (flow) increases more than total peripheral resistance (TPR), resulting in an increase in LV afterload, which initiates cardiac remodeling. According to the law of Laplace, an increase in afterload causes an increase in wall stress. In order to reduce wall stress, concentric remodeling occurs with an increase in overall wall thickness. However, in some patients, asymmetric remodeling develops rather than concentric remodeling. In particular, asymmetric remodeling is commonly observed in patients with an increase in LV afterload due to aortic stenosis and systemic hypertension (10–25%) [23]. This may be explained by the fact that the ventricular septum has a larger bending radius than the posterior wall. During contraction, this larger bending radius leads to greater myocardial stress of the septal wall. This initiates a more pronounced hypertrophic response leading to asymmetric remodeling of the septal wall [24]. The same mechanism may be responsible for the findings in athletes in the present study. Yet, it remains unclear why only some of the athletes in this study express asymmetric remodeling. One could speculate that these athletes have a genetic predisposition for developing an increase in myocardial wall thickness in response to an increase in LV afterload [24]. It is also known that an increase in afterload leads to an impairment of myocardial relaxation [25]. This theory is supported by Hayashida et al. [26], who show that a greater impairment of myocardial relaxation is observed with increasing wall thickness. In this way, afterload and (asymmetric) cardiac remodeling can alter diastolic LV function and eventually lead to diastolic dysfunction.

This altered diastolic function could possibly be an explanation for the observed ST-segment depression in athletes without the presence of epicardial CAD. As shown in the present study, there was a significant prolongation of the DT of the early left ventricular filling velocity in athletes with abnormal ET results. This prolonged DT reflects an impaired left ventricular relaxation. Ventricular relaxation is one of the major determinants of diastolic filling and is characterized by the duration of the decrease of LV pressure after systole. A prolonged DT indicates that LV end diastolic pressure (LVEDP) is elevated. It is known that a minimal perfusion pressure is necessary to maintain patency of the coronary microvasculature [27]. As a result of an elevated LVEDP, the critical closing pressure of the coronary microvasculature could be exceeded. Due to this phenomenon, the perfusion gradient is compromised, resulting in a reduced coronary flow. In turn, the reduced coronary flow leads to an ischemic response, which further aggravates the LVEDP through ischemia-induced alterations in the diastolic pressure–volume relationship.

Another possible explanation for the ST-segment depression could also be related to the observed cardiac remodeling. It is known that an increase in myocardial mass should be evenly compensated with an increase in angiogenesis to fulfill the requirements for increased oxygen consumption [11]. However, this response has been found to be critically dependent on age [11], as angiogenesis does not outweigh the increase in LV mass in the elderly [28]. The present study included athletes with a mean age of 52.9 years. It is feasible to think that there might be an imbalance between myocardial mass and angiogenesis, especially in the group of athletes with asymmetric cardiac remodeling.

It has also been shown that [27, 29] this imbalance leads to a reduced vasodilator reserve. A previous study [11] shows that an active vasomotor tone is required to maintain subendocardial perfusion by creating a flow gradient to the deeper myocardial layers. In the case of a defect in the vasomotor tone, there is an impaired regulation of myocardial perfusion due to the diminished gradient from epicardium to endocardium. This dysfunctional vasodilation may be caused by a reduction in availability of the endothelium-derived relaxing factor (EDRF), also known as nitric oxide (NO), and an increase of endothelin-1 (ET-1) levels. Due to the imbalance between vasodilation and vasoconstriction, an endothelial vasodilator dysfunction can develop [30]. Therefore, endothelial dysfunction could be an explanation of exercise-induced ischemia in athletes, although previous studies show conflicting results of both increased endothelial function [31], similar [32] and reduced endothelial function [14] in athletes. In athletes, it is known that an increased myocardial blood transition time enables higher oxygen extraction levels together with a lower myocardial blood flow and higher vascular resistance [33]. All these adaptations are key to deliver adequate oxygen supply to the myocardium in response to the needs during exercise in the athletic heart. In the case of an imbalance between myocardial mass and angiogenesis together with a reduced vasomotor tone, myocardial oxygen delivery is reduced, which can induce exercise-induced ischemia.

Myocardial ischemia with ST-segment depression can also occur due to cardiac compressive forces. During basal conditions, systolic contraction impedes myocardial blood flow resulting in primarily diastolic filling of the coronary vasculature. However, during exercise 40–50% of the coronary blood flow occurs during systole as the diastolic interval decreases with higher heart rates. It is feasible to think that the observed increase in septal wall thickness, together with the above-mentioned imbalance, compresses the coronary microvasculature. These factors, solely or combined, could cause the observed ST-segment depression as an expression of myocardial ischemia.

Clinical implications

The high prevalence of abnormal ET results in athletes requires consideration, because an erroneous diagnosis may have important consequences. For instance, a false diagnosis of cardiac disease warrants unnecessary activity restriction or even disqualification from sports, while an incorrect diagnosis may jeopardize the life of an athlete [34]. In addition, athletes with abnormal ET results undergo invasive diagnostic procedures, which are accompanied with higher health care costs. In order to reduce the high number of abnormal ET results, it is necessary to elucidate associated mechanisms and identify predictors that can be used to improve the positive predictive value of electrocardiography in asymptomatic athletes. This study shows a possible relationship between LV asymmetric remodeling and the occurrence of abnormal ET results. However, given the small differences in echocardiographic values between groups, cardiac remodeling only seems to play a limited role. Therefore, other sports-related mechanisms that may be related to the development of STT changes during exercise, such as microvascular dysfunction, insufficient density of myocardial capillaries relative to myocardial mass and compression of the microvascular arteries due to high ventricular filling pressure, should be explored.


There are several limitations that should be acknowledged. First, LV mass was measured via echocardiography. M-mode echocardiography is the most widely used technique in the evaluation of the LV mass, because of the relatively low costs and the rapid and non-invasive character. However, M-mode echocardiography has important limitations particularly in subjects with abnormal LV geometry as it is known that the accuracy of LV mass measurement declines in dilated left ventricles [35]. Also, it is known that M-mode echocardiography overestimates LV mass when compared with magnetic Resonance Imaging (MRI) and there is a high test-retest variability in LV mass among one single individual of approximately 35 g (the smallest detectable change with 95% confidence interval) [36]. Therefore, in order to detect a change in LV mass of at least 10 g, approximately 200 subjects per group would be necessary [37]. Another limiting factor is the intra- and interobserver variability in the measurement of LV mass. Literature showed that there is an intraobserver variability of 19 g and an interobserver variability of 24 g [38]. MRI is the gold standard for accurate assessment of the LV mass, but this technique is relatively expensive, time consuming and not feasible for all patients [39]. Therefore, it is less suitable for routine clinical screening for cardiac remodeling in athletes. Second, the primary study was not powered to detect a difference in LV mass in athletes which could lead to a type II error in the present study. Finally, the study population consisted primarily of male athletes who practice high-static, high-dynamic sports. Therefore, it was not possible to make a reliable statement about the correlation of LV remodeling on abnormal ET results in female athletes and athletes who perform low-static, low-dynamic exercise or other types of sports.


Athletes with abnormal ET result did not show a higher LV mass when compared to athletes with a normal ET result. However, these athletes did show a pattern of asymmetric cardiac remodeling due to a greater IVS thickness, together with an altered diastolic function as indicated by a prolonged DT. Yet, as these differences were small and values were still within the normal range, these results suggest that cardiac remodeling only plays a limited role in the occurrence of abnormal ET results in athletes.



Pre-participation screening


Exercise testing


Coronary artery disease


Left ventricular/left ventricle




Left ventricular end diastolic dimension


Interventricular septal thickness end diastole


Left ventricular posterior wall thickness end diastole


Relative wall thickness


Deceleration time



The authors wish to thank the participants, the Department of Sports Medicine and the echocardiography division of the Department of Cardiology. The results of the study are presented clearly, honestly, and without fabrication, falsification or inappropriate data manipulation.


The authors declare that they received no funding.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

DS collected, analyzed and interpreted the patient data. DS and HK were major contributors in writing the manuscript. JH, HK and PD analyzed and interpreted the patient data and reviewed the manuscript prior to admission. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study is approved by the local ethics committee with reference number 2014–08. This statement is included in the methods section in the manuscript. Written informed consent is available in all study subjects.

Consent for publication

Not applicable.

Competing interest

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Cardiology, Máxima Medical Center, De Run 4600, 5504, DB, Veldhoven, The Netherlands
Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands


  1. Maron BJ, Levine BD, Washington RL, Baggish AL, Kovacs RJ, Maron MS. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 2: Preparticipation screening for cardiovascular disease in competitive athletes: a scientific statement from the American heart Associ. J Am Coll Cardiol. 2015;66:2356–61. ArticlePubMedGoogle Scholar
  2. Corrado D, Schmied C, Basso C, Borjesson M, Schiavon M, Pelliccia A, et al. Risk of sports: do we need a pre-participation screening for competitive and leisure athletes? Eur Heart J. 2011;32:934–44.View ArticleGoogle Scholar
  3. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden cardiovascular death in young competitive athletes. JAMA. 2006;296:1593–601.View ArticleGoogle Scholar
  4. Harmon KG, Zigman M, Drezner JA. The effectiveness of screening history, physical exam, and ECG to detect potentially lethal cardiac disorders in athletes: a systematic review/meta-analysis. J Electrocardiol. 2015;48:329–38. ArticlePubMedGoogle Scholar
  5. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al. International recommendations for electrocardiographic interpretation in athletes. J Am Coll Cardiol. 2017;69:1057–75.View ArticleGoogle Scholar
  6. Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Terradellas JB, et al. Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Europace. 2017;19:139–63.View ArticleGoogle Scholar
  7. Gibbons LW, Mitchell TL, Wei M, Blair SN, Cooper KH. Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. Am J Cardiol. 2000;86:53–8.View ArticleGoogle Scholar
  8. Katzel LI, Fleg JL, Busby-Whitehead MJ, Sorkin JD, Becker LC, Lakatta EG, et al. Exercise-induced silent myocardial ischemia in master athletes. Am J Cardiol. 1998;81:261–5. ArticlePubMedGoogle Scholar
  9. van de Sande DAJP, Breuer MAW, Kemps HMC. Utility of Exercise electrocardiography in pre-participation screening in asymptomatic athletes: a systematic review. Sport Med. 2016;46:1155–64.View ArticleGoogle Scholar
  10. Shimizu M, Ino H, Okeie K, Emoto Y, Yamaguchi M, Yasuda T, et al. Exercise-induced ST-segment depression and systolic dysfunction in patients with nonobstructive hypertrophic cardiomyopathy. Am Heart J. 2000;140:52–60.View ArticleGoogle Scholar
  11. Duncker D, Bache R. Regulation of coronary blood flow during exercise. Physiol Rev. 2008;88:1009–86. ArticlePubMedGoogle Scholar
  12. Prior DL, La Gerche A. The athlete’s heart. Heart. 2012;98:947–55. ArticlePubMedGoogle Scholar
  13. Hill J, Timmis A. Exercise tolerance testing. BMJ. 2002;324:1084–7 ArticleGoogle Scholar
  14. Laaksonen MS, Heinonen I, Luotolahti M, Knuuti J, Kalliokoski KK. V̇O2peak, myocardial hypertrophy, and myocardial blood flow in endurance-trained men. Med Sci Sports Exerc. 2014;46:1498–505.View ArticleGoogle Scholar
  15. van Middelkoop M, van Linschoten R, Berger MY, Koes BW, Bierma-Zeinstra SM. Knee complaints seen in general practice: active sport participants versus non-sport participants. BMC Musculoskelet Disord. 2008;9:36.View ArticleGoogle Scholar
  16. van de Sande D, Schoots T, JH Doevendans P, Kemps H. O2 Pulse Patterns in Male Master Athletes with Normal and Abnormal Exercise Tests. Med Sci Sports Exerc. 2018.
  17. Mitchell JH, Haskell W, Snell P, Van Camp SP, Exercise RTO. Task force 8: Classi cation of sports. Response. 2005;45:1364–7.Google Scholar
  18. Oh JK, Seward J, Tajik A. The Echo manual, 3th edition. Wolters Kluwer; 2006.Google Scholar
  19. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–71. ArticlePubMedGoogle Scholar
  20. Pigozzi F. Role of exercise stress test in master athletes. Br J Sports Med. 2005;39:527–31. ArticlePubMedPubMed CentralGoogle Scholar
  21. Spirito P, Maron BJ, Bonow RO, Epstein SE. Prevalence and significance of an abnormal S-T segment response to exercise in a young athletic population. Am J Cardiol. 1983;51:1663–6. ArticleGoogle Scholar
  22. Arts F, Kuipers H. The relation between power output, oxygen uptake and heart rate in male athletes. Int J Sports Med. 1994;15:228–31.View ArticleGoogle Scholar
  23. Rodrigues JCL, Amadu AM, Dastidar AG, Hassan N, Lyen SM, Lawton CB, et al. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance. Eur Hear J – Cardiovasc Imaging. 2016;17:1405–13. ArticleGoogle Scholar
  24. Kwiecinski J, Chin CWL, Everett RJ, White AC, Semple S, Yeung E, et al. Adverse prognosis associated with asymmetric myocardial thickening in aortic stenosis. Eur Hear J - Cardiovasc Imaging. 2017;19:1–10. ArticleGoogle Scholar
  25. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart. 2006;92:712–8. ArticlePubMedPubMed CentralGoogle Scholar
  26. Hayashida W, Kumada T, Kohno F, Noda M, Ishikawa N, Kojima J, et al. Left ventricular regional relaxation and its nonuniformity in hypertrophic nonobstructive cardiomyopathy. Circulation. 1991;84:1496–504 ArticleGoogle Scholar
  27. Cannon RO, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 1985;71:234–43. ArticlePubMedGoogle Scholar
  28. Jacobs T, Bell R, McClements J. Exercise, age and the development of the myocardial vasculature. Growth. 1984;48:148–57.PubMedGoogle Scholar
  29. Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol. 1998;31:1089–96. ArticlePubMedGoogle Scholar
  30. Van De Sande DAJP, Hoogsteen J, Liem IH, Kemps HMC. Athlete’s syndrome X. Int J Cardiol. 2014;177:e49–50. ArticlePubMedGoogle Scholar
  31. Toraa M, Pouillard F, Merlet P, Friemel F. Cardiac hypertrophy and coronary reserve in endurance athletes. Can J Appl Physiol. 1999;24:87–95.PubMedGoogle Scholar
  32. Heinonen I, Nesterov SV, Liukko K, Kemppainen J, Någren K, Luotolahti M, et al. Myocardial blood flow and adenosine A2Areceptor density in endurance athletes and untrained men. J Physiol. 2008;586:5193–202.View ArticleGoogle Scholar
  33. Heinonen I, Kudomi N, Kemppainen J, Kiviniemi A, Noponen T, Luotolahti M, et al. Myocardial blood flow and its transit time, oxygen utilization, and efficiency of highly endurance-trained human heart. Basic Res Cardiol. 2014;109.Google Scholar
  34. Rawlins J, Bhan A, Sharma S. Left ventricular hypertrophy in athletes. Eur J Echocardiogr. 2009;10:350–6.View ArticleGoogle Scholar
  35. Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete s heart : a meta-analysis of cardiac structure and function. Circulation. 2000;101:336–44. ArticlePubMedGoogle Scholar
  36. Gottdiener JS, Livengood SV, Meyer PS, Chase GA. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol. 1995;25:424–30. ArticlePubMedGoogle Scholar
  37. Perdrix L, Mansencal N, Cocheteux B, Chatellier G, Bissery A, Diebold B, et al. How to calculate left ventricular mass in routine practice? An echocardiographic versus cardiac magnetic resonance study. Arch Cardiovasc Dis. 2011;104:343–51. ArticlePubMedGoogle Scholar
  38. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials: a report from the american society of echocardiography’s guidelines and standards committee and the task force on echocardiography in clinical trials. J Am Soc Echocardiogr. 2004;17:1086–119.PubMedGoogle Scholar
  39. Prakken NH, Velthuis BK, Teske AJ, Mosterd A, Mali WP, Cramer MJ. Cardiac MRI reference values for athletes and nonathletes corrected for body surface area, training hours/week and sex. Eur J Cardiovasc Prev Rehabil. 2010;17:198–203. ArticlePubMedGoogle Scholar


© The Author(s). 2019